This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antman, E. M. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Antman, E. M. Articles by Braunwald, E. Related Collections Related Article

CLINICAL RESEARCH: ACUTE CORONARY SYNDROME

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction) Analysis

Elliott M. Antman, MD, FACC^_*,_*, Stephen D. Wiviott, MD^_*, Sabina A. Murphy, MPH^_*, Juri Voitk, MD, FACC, Yonathan Hasin, MD, Petr Widimsky, MD, DrSc, Harish Chandna, MBBS, FACC^¶, William Macias, MD, PhD^||, Carolyn H. McCabe, BS^_* and Eugene Braunwald, MD, MACC^_*

^_* Brigham and Women's Hospital, Boston, Massachusetts
North Estonian Regional Hospital, Tallinn, Estonia
The Kittner and Davidai Institute of Cardiology Center, Poriya, Israel
Cardiocenter, Charles University and University Hospital Vinohrady, Prague, Czech Republic
^¶ Detar Hospital, Victoria, Texas
^|| Eli Lilly Research Laboratories, Indianapolis, Indiana.

Manuscript received January 17, 2008; revised manuscript received March 7, 2008, accepted April 7, 2008.

^_* Reprint requests and correspondence: Dr. Elliott M. Antman, Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, 350 Longwood Avenue, 1st Floor, Boston, Massachusetts 02115. (Email: eantman{at}rics.bwh.harvard.edu).

Objectives: We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction) analysis.

Background: Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding.

Methods: Landmark analyses for efficacy, safety, and net clinical benefit were performed from randomization to day 3 and from day 3 to the end of the trial.

Results: Significant reductions in ischemic events, including myocardial infarction, stent thrombosis, and urgent target vessel revascularization, were observed with the use of prasugrel both during the first 3 days and from 3 days to the end of the trial. Thrombolysis In Myocardial Infarction major non–coronary artery bypass graft bleeding was similar to clopidogrel during the first 3 days but was significantly greater with the use of prasugrel from 3 days to the end of the study. Net clinical benefit significantly favored prasugrel both early and late in the trial.

Conclusions: Both the loading dose and maintenance dose of prasugrel were superior to clopidogrel for the reduction of ischemic events. This result emphasizes the importance of maintaining high levels of inhibition of platelet aggregation via P2Y₁₂ receptor inhibition, not only for the prevention of periprocedural ischemic events but also during long-term follow-up. The excess major bleeding observed with the use of prasugrel occurred predominantly during the maintenance phase. Approaches to reduce the relative excess of bleeding with prasugrel should focus on the maintenance dose (e.g., reduction in maintenance dose in previously reported high-risk subgroups, such as the elderly and those patients with low body weight). (A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention; NCT00097591)

Abbreviations and Acronyms   ACS = acute coronary syndrome   CABG = coronary artery bypass graft   HR = hazard ratio   IPA = inhibition of platelet aggregation   MI = myocardial infarction   PCI = percutaneous coronary intervention   TIMI = Thrombolysis In Myocardial Infarction   UA/NSTEMI = unstable angina/non–ST-segment myocardial infarction

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A23-A24. [Full Text] [PDF]

This article has been cited by other articles:

				Authors/Task Force Members, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur. Heart J., December 1, 2011; 32(23): 2999 - 3054. [Full Text] [PDF]

				M. J. Price and E. J. Topol Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Intervention--Reply JAMA, June 22, 2011; 305(24): 2521 - 2522. [Full Text] [PDF]

				R. Hall and C. D. Mazer Review Article: Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period Anesth. Analg., February 1, 2011; 112(2): 292 - 318. [Abstract] [Full Text] [PDF]

				R. E. O'Connor, W. Brady, S. C. Brooks, D. Diercks, J. Egan, C. Ghaemmaghami, V. Menon, B. J. O'Neil, A. H. Travers, and D. Yannopoulos Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Circulation, November 2, 2010; 122(18_suppl_3): S787 - S817. [Full Text] [PDF]

				R. E. O'Connor, L. Bossaert, H.-R. Arntz, S. C. Brooks, D. Diercks, G. Feitosa-Filho, J. P. Nolan, T. L. V. Hoek, D. L. Walters, A. Wong, et al. Part 9: Acute Coronary Syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Circulation, October 19, 2010; 122(16_suppl_2): S422 - S465. [Full Text] [PDF]

				B. Fletcher and K. K. Thalinger Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention Crit. Care Nurse, October 1, 2010; 30(5): 45 - 54. [Full Text] [PDF]

				S. A. Spinler Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk Am. J. Health Syst. Pharm., August 1, 2010; 67(15_Supplement_7): S7 - S17. [Abstract] [Full Text] [PDF]

				L. Testa, R. Bhindi, W. J. Van Gaal, R. A. Latini, S. Pizzocri, S. Lanotte, G. G. L. Biondi Zoccai, M. Valgimigli, M. L. Laudisa, N. Brambilla, et al. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel QJM, June 1, 2010; 103(6): 367 - 377. [Abstract] [Full Text] [PDF]

				S. A. Mousa, W. P. Jeske, and J. Fareed Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist Clinical and Applied Thrombosis/Hemostasis, April 1, 2010; 16(2): 170 - 176. [Abstract] [PDF]

				N. A. Farid, A. Kurihara, and S. A. Wrighton Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans J. Clin. Pharmacol., February 1, 2010; 50(2): 126 - 142. [Abstract] [Full Text] [PDF]

				M. Vasa-Nicotera and T. Gershlick Chapter 29 Stent thrombosis Oxford Textbook of Interventional Cardiology, January 1, 2010; 1(1): med-9780199569083-chapter - med-9780199569083-chapter. [Abstract] [Full Text]

				L. D. LAZAR and A. M. LINCOFF Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk Cleveland Clinic Journal of Medicine, December 1, 2009; 76(12): 707 - 714. [Abstract] [Full Text] [PDF]

				G. Montalescot Benefits for specific subpopulations in TRITON-TIMI 38 Eur. Heart J. Suppl., December 1, 2009; 11(suppl_G): G18 - G24. [Abstract] [Full Text] [PDF]

				C. RAYMOND and V. MENON Dual antiplatelet therapy in coronary artery disease: A case-based approach Cleveland Clinic Journal of Medicine, November 1, 2009; 76(11): 663 - 670. [Abstract] [Full Text] [PDF]

				M. O'Donoghue, E. M. Antman, E. Braunwald, S. A. Murphy, P. G. Steg, A. Finkelstein, W. F. Penny, V. Fridrich, C. H. McCabe, M. S. Sabatine, et al. The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis J. Am. Coll. Cardiol., August 18, 2009; 54(8): 678 - 685. [Abstract] [Full Text] [PDF]

				S. D. Wiviott, E. Braunwald, S. A. Murphy, C. H. McCabe, E. M. Antman, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W.A. Verheugt, S. G. Goodman, et al. Response to Letter Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38" Circulation, June 30, 2009; 119(25): e602 - e603. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008 J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1095 - 1103. [Full Text] [PDF]